Search
Curcuma xanthorrhiza oil
go.drugbank.com/drugs/DB11265ApprovedNutraceutical_Curcuma xanthorrhiza_ oil is comprised of 1-2% of curcumin and 3-12% volatile oil, which mainly contains sesquiterpenes, 44.5% of xanthorrhizol, and a small amount of [DB01744] [F114]. … _Curcuma xanthorrhiza_ oil is extracted from _Curcuma xanthorrhiza_ Roxb., a member of the ginger family (_Zingiberaceae_) that is widely distributed in the region of Southeastern Asia [A33162].
Loxapine
go.drugbank.com/drugs/DB00408ApprovedInvestigationalAn antipsychotic agent used in schizophrenia. [PubChem]
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Dopamine D2 Receptor AntagonistsPalopegteriparatide
go.drugbank.com/drugs/DB18676ApprovedInvestigational[L51134] Palopegteriparatide was first approved by the EMA on November 17, 2023, for the treatment of hyperparathyroidism.[L51134] On August 8, 2024, palopegteriparatide was also approved by the FDA. … [L51134] PTH(1-34) contains the N-terminal part of the endogenous PTH molecule.
Synonyms: )-peptide of parathyroid hormone (Homo sapiens parath, Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34Aliskiren
go.drugbank.com/drugs/DB09026ApprovedInvestigationalAliskiren is the first drug in the renin inhibitor drug class and is used for the treatment of hypertension. … [L14018] Aliskiren has been proven to efficacious in reducing blood pressure when used alone or in conjunction with other antihypertensive agents.[A203624]
Categories: Agents Acting on the Renin-Angiotensin SystemRevefenacin
go.drugbank.com/drugs/DB11855ApprovedInvestigational[A40026] It was developed by Theravance Biopharma and FDA approved on November 9, 2018.[L4818] … The labile primary amide in the structure produces a "soft-drug" site that allows rapid systemic clearance and minimizing of the systemically mediated adverse reactions.
Dithiazanine
go.drugbank.com/drugs/DB11516ApprovedVet approvedWithdrawnDithiazanine is a highly potent anthelmintic, introduced in 1959 for the treatment of strongyloid worms and whipworms. However, its use is severely limited due to its toxicity. … Dithiazanine iodide was associated with eight fatal cases of severe acidosis and shock between 1961 and 1964.
Categories: Compounds used in a research, industrial, or household settingBetrixaban
go.drugbank.com/drugs/DB12364ApprovedVTE can be manifested as deep vein thrombosis or pulmonary embolism and it is a leading cause of preventable death in hospitalized patients [A27287]. … Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa [A7708].
Synonyms: N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, N-(5-chloropyridin-2-yl)-2-[[4-(N,N-dimethylcarbamimidoyl)benzoyl]amino]-5-methoxybenzamideAltropane
go.drugbank.com/drugs/DB04947InvestigationalBoston Life Sciences (BLS) is developing Altropane as a potential radio-imaging agent to be used with single photon emission tomography (SPECT), for the early diagnosis of Parkinson's disease (PD) and
Marnetegragene autotemcel
go.drugbank.com/drugs/DB17595Approved[L56116, A275467] Allogeneic hematopoietic stem cell transplant is a curative option but is limited by issues such as donor availability, a high incidence of graft-versus-host disease, and graft failure … [L56116, A275467] Marnetegragene autotemcel, also known as marne-cel, is an autologous hematopoietic stem cell-based gene therapy created from the patient's own hematopoietic stem cells.
Glofitamab
go.drugbank.com/drugs/DB16371ApprovedInvestigational, after two or more lines of systemic therapy under accelerated approval based on response rate and durability of response. … This approval is based on the positive results obtained from the phase I/II NP30179 study, where 35.2% of study participants achieved a complete response.[L47451]